This paper presents a new concept combining flexible organic light emitting diode (OLED) display technology with fluorescent biorecognition microarray technology to fabricate point-of-care immunobiosensors. Our approach is designed to leverage commercial OLED display technology to reduce pre-functionalized biosensor substrate costs to pennies per cm 2 combined with leveraging the display industries ability to manufacture an immense number of low-cost consumer electronic products annually. For this work, we demonstrate that our new approach using high brightness flexible OLED display technology combined with a charge integrating readout circuit and optical filters can offer point-of-care diagnostic sensitivity at or below 10 pg/mL, which approaches the lower limit of detection (LLOD) of typical clinical laboratory instrumentation.

The viability of a new biophotonic alternative to conventional prescription-drug-based treatments is explored for inflammatory disease and mental health disorders using a non-invasive drug-free optogeneticsbased therapy to treat patients by optically stimulating selected afferent branches of the auricular vagus nerve transcutaneously via the outer ear using a high-resolution, addressable array of organic light emitting diodes (OLED) manufactured on a flexible plastic substrate. Preliminary analysis and optical measurements indicate that our 620 nm flexible red OLED display technology is bright enough to induce therapeutic optical stimulation in optogenetically modified neural tissue.

No abstract

No abstract

No abstract